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Background: The current perspective for the search of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA)
reductase inhibitor has been shifted towards a natural agent also having antioxidant property. Thus, this study was
intended to isolate and identify the bioactive compounds from methanolic extract of Ficus virens bark (FVBM) and
to evaluate their antioxidant, HMG-CoA reductase inhibitory and hypolipidemic activity.
Methods: Bioactivity guided fractionation and isolation of bioactive compound from FVBM extract has been done
to isolate and characterize the potent HMG-CoA reductase (HMGR) inhibitor with antioxidant activity by using
repeated extensive column chromatography followed by spectroscopic methods, including Infrared (IR), 1H &
13C nuclear magnetic resonance (NMR) and Mass spectrum analysis. The in vitro HMGR inhibition and enzyme
kinetic assay was determined using HMG-CoA as substrate. In addition, antioxidant activity of the new isolated
compound, was measured using 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assay and FRAP value.
In-silico molecular informatics of HMGR enzyme type inhibition and pharmacokinetics data of the new compound
was further evaluated through molecular docking and ADME-T studies. Further, in-vivo hypolipidemic property of
FVBM extract and newly isolated compound was also analyzed in triton-WR 1339 induced rats.
Results: Thereby, we report the discovery of n-Octadecanyl-O-α-D-glucopyranosyl(6′→ 1″)-O-α-D-glucopyranoside
(F18) as a novel HMG-CoA reductase inhibitor with strong antioxidant property. This inhibitor exhibited not only
higher free radical scavenging activity but also marked HMG-CoA reductase inhibitory activity with an IC50 value of
84 ± 2.8 ng/ml. This inhibitory activity concurred with kinetic study that showed inhibition constant (Ki) of 84 ng/ml
via an uncompetitive mode of inhibition. The inhibition was also corroborated by molecular docking analysis and
in silico pharmacokinetics data. The in vivo study revealed that administration of FVBM extract (at higher dose,
100 mg/rat) and the inhibitor (1 mg/rat) to Triton WR-1339-induced hyperlipidemic rats significantly ameliorated
the altered levels of plasma lipids and lipoproteins including hepatic HMG-CoA reductase activity; this effect was
comparable to the effect of standard drug atorvastatin.
Conclusions: The in vitro, in silico and in vivo results clearly demonstrated the antioxidant potential and therapeutic
efficacy of the inhibitor as an alternate drug against hyperlipidemia.
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Cardiovascular disease (CVD) is the major cause of
death in developed and developing countries [1,2]. It is
well known that three major risk factors for CVD are
hypercholesterolemia, smoking and hypertension [3].
Several studies have established that elevated blood chol-
esterol along with triglyceride (TG) level is a major
cause and initial risk factor of atherosclerosis and subse-
quent CVD [4,5]. Endogenous cholesterol biosynthesis
in the liver is mainly controlled by rate limiting enzyme,
3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase,
which catalyzes the conversion of HMG-CoA to meva-
lonic acid [6]. Drugs that lower cholesterol level mainly
work by inhibiting the HMG-CoA reductase activity
[7,8]. Despite the significant clinical benefits provided by
statins [9], many patients do not achieve the recom-
mended low-density lipoprotein (LDL) and high-density
lipoprotein (HDL) cholesterol target goals [10]. More-
over, elevated lipid level results in accumulation of LDL
in subendothelial space of arteries, where it undergoes
through an oxidative modification to form oxidized
LDL, which is highly atherogenic [5,11]. Moreover, the
use of statins is not preferred in more than 40% of pa-
tients, mostly due to the occurrence of several side ef-
fects including myalgia, myopathy, liver disease, and
rhabdomyolysis in more severe cases [12,13]. Statins in
combination with fibrates show significant benefit at
higher doses but are also associated with severe side ef-
fects [14]. This limits the use of statins and incites a
search of new natural drugs to combat hypercholesterol-
emia as well as cholesterol induced oxidative stress and
atherosclerosis.
Medicinal plants are potential sources of therapeutic
compounds. Therefore, searching for natural and select-
ive HMG-CoA reductase inhibitors with antioxidant
property as an alternative to synthetic drugs is of great
interest. One of the promising breakthroughs in the drug
discovery is the use of mechanism-based screening for a
bioassay guided fractionation such as isolation of mevas-
tatin from Penicillium citrinum [15,16]. Ficus virens Ait
(FV) (Moraceae) has been known traditionally for its
medicinal properties, which include its use in the treat-
ment of blood diseases, uterus, burning sensation, hallu-
cination, and unconsciousness [17]. This plant is also
known to possess significant amount of phenolic com-
pounds and a potent antioxidant activity [18,19]. In a
continuous bid to search new hypolipidemic drug with
antioxidant property from plant origin, we have recently
demonstrated that among all sequentially extracted frac-
tions of Ficus virens, Ficus virens bark methanolic extract
(FVBM) posses a significant HMG-CoA reductase in-
hibitory activity along with antioxidant property [20].
On this basis, the present study was premeditated to iso-
late and characterize the bioactive compounds fromFVBM extract, and subsequently to evaluate their anti-
oxidant and HMG-CoA reductase inhibitory activity
using in vitro and in silico approaches. Furthermore,
in vivo lipid lowering activity and the possible mechan-
ism of action of FVBM extract and the bioactive com-
pound have also been discussed.
Materials and methods
Chemical reagents
HMG-CoA reductase assay kit was purchased from
Sigma-Aldrich Co. (USA). 2, 2-diphenyl-1-picrylhydrazyl
(DPPH), Triton WR-1339, 2,4,6-tri(2-pyridyl)-s-triazine
(TPTZ), and silica gel (60–120 mesh) were purchased
from HiMedia Laboratories, Mumbai, India. Total chol-
esterol (TC) and triglycerides (TG) kits was procured
from Merck Diagnostic (German). All other chemicals
and solvents used in this study were of analytical grade.
Plant material and extraction
The plant material, fresh stem bark of Ficus virens Ait
(FVB), was collected from herbal garden of the Depart-
ment of Pharmacy, Integral University, Lucknow, India.
Plant was authenticated by Dr. Tariq Husain of the herb-
arium division of National Botanical Research Institute,
Lucknow, India, and has been deposited in herbarium
vide Accession No. 97959. The sequential extraction of
FVB was performed to obtain methanolic fraction [20].
Bioactivity guided isolation and characterization of active
compound
The dried residue of FVBM extract was subjected to sil-
ica gel (60–120 mesh) column chromatography starting
with CHCl3/MeOH (98:02, v/v) as eluent, followed by a
gradient of increasing methanol percentage (i.e., increas-
ing polarity). Twenty fractions (F1-F20) of 200 ml each
were collected and tested for antioxidant and HMG-
CoA reductase inhibitory activity as described below.
The most bioactive fraction (F18) was subjected to 1D
and 2D thin layer chromatography (TLC) in order to
check the purity and determination of the structure of
the bioactive compound by using the following tech-
niques: infrared (IR), 1H and 13C nuclear magnetic res-
onance (NMR), and mass spectroscopy. The electrospray
mass spectra were recorded on THERMO Finnigan
LCQ Advantage max ion trap mass spectrometer. The
samples (10 μl) (dissolved in solvent such as methanol/
acetonitrile/water) were introduced into the ESI source
through Finnigan surveyor autosampler. The mobile phase
was 90:10 Methanol/ACN: H2O flowed at the rate of
250 μl/min by MS pump. Ion spray voltage was set at
5.3 KV and capillary voltage at 34 V. Each MS scan was re-
corded for to 2.5 min and the final spectra were average
of over 10 scans at peak in TIC. The IR spectra of the
antioxidant compounds were recorded on Perkin-Elmer
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NMR spectra were recorded on BrukerDRX-300, using
methanol CD3OD as solvent. 1D and 2D TLC were per-
formed on silica gel 60 F254 aluminum plate.
In vitro antioxidant assays
The DPPH radical scavenging activity was measured ac-
cording to the standard method of Williams et al. [21].
Measurement of ferric reducing antioxidant power
(FRAP) of the various fractions (F1-F20) was carried out
according to the procedure of Benzie and Strain [22]
with some modifications [23].
In vitro cell-free assay and kinetic studies of HMG-CoA
reductase
The HMG-CoA reductase assay kit from Sigma-Aldrich
(St. Louis, MO, USA) based on the catalytic domain of
the human enzyme (recombinant GST fusion protein
expressed in E. coli) was used, following the manufac-
turer’s protocol. The kit was used for a rapid screening
of all the fractions isolated from FVBM extract and for
the identification of the most effective bioactive com-
pound with statin-like activities [20].
In order to determine the mode of inhibition of
HMG-CoA reductase enzymatic activity, the NADPH
concentration was fixed to 400 μM and HMG-CoA was
used in the range of 100–500 μM in the absence and
presence of different concentrations (10, 50, 100, 500,
1000 ng/ml) of the fraction showing maximum inhib-
ition. Enzyme kinetic parameters (Km and Vmax), were
evaluated using the non-linear regression method based
on Michaelis-Menten equation and the type of inhibition
was identified using Lineweaver-Burk plot, and Ki was
determined by Dixon plot [24,25].
Docking analysis
Crystallographic structures used in this study for HMG-
CoA reductase in complex with atorvastatin (PDB ID:
1HWK) was retrieved from the Research Collaboratory
for Structural Bioinformatics (RCSB) Protein Data Bank
(www.pdb.org). The 3D structures of the ligands were
prepared with Chembiodraw Ultra 12.0. Ligand-protein
docking was performed using AutoDock4.2 program.
This program starts with the ligand in an arbitrary con-
formation and finds favorable dockings in a protein
binding site using the Lamarckian genetic algorithm to
create a set of possible conformations [26] to dock prav-
astatin. The software docked the novel compound (F18)
isolated from FVBM extract into the catalytic portion of
HMG-CoA reductase enzyme using an empirical scoring
function based on the free binding energy [27]. After
execution of Autodock, several conformations of ligand
in complex with the receptor were obtained, which
were finally ranked on the basis of binding energy andinhibition constant (Ki). The resulting conformations were
visualized in the discovery studio visualizer (version 3.2).
Absorption, distribution, metabolism, and excretion
(ADME) studies
Pharmacokinetic parameters, such as aqueous solubility
[28], blood–brain-barrier (BBB) penetration [29], plasma
protein binding (PPB) [30], intestinal absorption [31]
and cytochrome P450 inhibition [32] for the compound
of most potent fraction (F18) and standard, were deter-
mined by using Descriptors algorithm in Accelrys Dis-
covery Studio 3.5 software. Standard levels for ADME
parameters are listed in Table 1.
In vivo hypolipidemic experiment
Animals
Male Sprague–Dawley (SD) rats weighing around 100–
150 g were procured from Indian Institute of Toxicology
Research Center, Lucknow. The study protocol was ap-
proved by Institutional Animal Ethics Committee (IAEC)
(registration number: IU/Biotech/project/CPCSEA/13/14).
The rats (5 per cage) were housed for one week in the ani-
mal house at temperature 21–22°C with 12 hour light and
dark cycles. The rats were given standard diet and water
ad libitum.
Dose preparation
Sequentially obtained FVBM extracts, the bioactive frac-
tion (F18), and the reference drug atorvastatin were dis-
solved in 10% dimethyl sulfoxide (DMSO) at different
concentrations and were homogenized with saline. The
doses of the extracts were selected on the basis of previ-
ously published reports [33,34].
Induction of hyperlipidemia
Hyperlipidemia was induced in rats by a single intraperi-
toneal injection of Triton WR-1339 (isooctylpolyox-
yethylene phenol) (200 mg/kg body weight) dissolved in
0.9% saline. After one hour of tritonization, the animals
were given food and water ad libitum [35]. Rats in nor-
mal control group were injected with saline only. The
rats were divided randomly and equally (5 rats in each
group) in groups as illustrated in Table 2. The plant ex-
tract, bioactive compound (F18) and atorvastatin sus-
pension was administered through gastric intubation in
single doses of 0.5 ml/rat, just after the tritonization;
and blood was withdrawn after 18 hours [36].
Collection of blood and plasma
At the end of the experiment, rats in each group were
anaesthetized; and blood was collected in heparinized
tubes by cardiac puncture. Plasma was separated from
blood by centrifugation at 2,500 rpm for 30 min, was ali-
quoted and stored at either 4 or–20°C for future use.
Table 1 Standard levels of ADME descriptors from Accelrys Discovery studio 2.5
Level Aqueous Solubility Intensity Intestinal Absorption Intensity BBBa Intensity PPBb % of binding CYP450c Value Hepatotoxicity
0 Extremely low Good Very high <90% Non inhibitor Extremely low
1 No, very low Moderate High >90% Inhibitor
2 Yes, low Low Medium >95%
3 Yes, good Very low Low
4 Yes, optimal Undefined Undefined
5 No, too soluble
6 Unknown
BBBa=Blood Brain Barrier, PPBb=Plasma Protein Binding, CYP450c=Cytochrome P450, Acceptable range of hydrogen bond acceptor=<10 and hydrogen
bond donor=<5.
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After the experiment, the liver from the rats was
promptly excised and chilled in ice-cold saline. After
washing with saline, it was blotted and weighed. Each
liver was cut into pieces; and 10 g of wet tissue was ho-
mogenized with 90 ml of chilled 0.1 M sodium phos-
phate buffer, pH 7.4, containing 1.17% KCl in a waring
blender. The homogenate was centrifuged at 1,000 rpm
for 10 min at 4°C, and finally was aliquoted and stored
at–20°C.Isolation of plasma LDL and HDL
Isolation of plasma LDL and HDL was carried out as de-
scribed by Wieland & Seidel [37] and Patsch et al. [38],
respectively.Determination of plasma triglyceride
Plasma TG was determined by using enzymatic kit
(Merck, India) based on glycerol-3-phosphate oxidase
peroxides (GPO-POD) method [39]. The very low dens-
ity lipoprotein-cholesterol (VLDL-C) in plasma was cal-
culated by dividing plasma TG values (mg/dl) by a factor
of 5 as described by Friedewald et al. [40].Determination of plasma TC, LDL-C and HDL-C
Plasma TC, LDL-C and HDL-C were determined by
using cholesterol enzymatic kit (Merck, India) based onTable 2 Protocol for the treatment of triton induce
hyperlipidemia in rats
Group Treatment/route of administration
NC Solvent system (vehicle)
HLC Hyperlipidemic control
FVT-1 Hyperlipidemic + plant extract (FVBM) (50 mg/rat)
FVT-2 Hyperlipidemic + plant extract (FVBM) (100 mg/rat)
CT Hyperlipidemic + bioactive compound (F18) (1 mg/rat)
AT Hyperlipidemic + standard (atorvastatin) (1 mg/rat)cholesterol oxidase phenol aminophenazone (CHOD-
PAP) method, and results were expressed as mg/dl.
Assay of HMG-CoA reductase activity in the liver
homogenate
HMG-CoA reductase enzyme activity in the liver hom-
ogenate was estimated indirectly as described by Rao
and Ramakrishnan [41]. Fresh 10% tissue homogenate
(1 g) was mixed with 9 ml of saline arsenate (0.1% so-
dium arsenate in physiological saline); and 10 ml of
5% perchloric acid was added. It was kept for 5 min at
room temperature and centrifuged at 2,000 rpm for
10 min. One milliliter of the supernatant from each tube
was taken out and mixed with 0.5 ml of freshly prepared
1 M aqueous hydroxylamine hydrochloride; whereas, for
the assay of HMG-CoA, 0.5 ml of alkaline hydroxylamine
hydrochloride was added and mixed. After an incubation
of 5 min at room temperature, 1.5 ml of 0.616 M ferric
chloride reagent containing 5.2% TCA, prepared in 0.65 N
HCl was added and mixed; and absorbance was read at
540 nm against a reagent blank using a Biospectrum-
kinetics spectrophotometer (Eppendorf) after 10 min of
incubation at room temperature.
Lactate dehydrogenase (LDH) assay
The LDH release assay was performed as per Ahmad
et al. [42]. In brief, the platelet rich plasma was obtained
from the supernatant resulting from the centrifugation
of blood at 200 g at room temperature. F18 (1 mg) and
Atorvastatin (1 mg) were incubated with platelet for 2 h
and the cytotoxicity of the F18 on platelets was mea-
sured by the release of lactate dehydrogenase (LDH)
from platelets suspension lysed with 1% Triton X-100
using the commercially available LDH kit (Biomedical
Research Services).
Data analysis
For all assays, samples were analyzed in triplicates, and
the results are being expressed as mean ± SD. IC50 (50%
inhibitory concentration) was calculated by Origin v. 6.0
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MA, USA), and the results were evaluated using one-way
analysis of variance (ANOVA) and two tailed Student’s t-test.
Statistically significant values were expressed as *p < 0.05,
**p < 0.01 and ***P < 0.001.
Results
In continuation to our previous study that illustrated pres-
ence of most potent antioxidant and HMG-CoA reductase
inhibitory property in FVBM extract [20], the current one
deals with isolation of the active compound through bio-
assay guided fractionation and its characterization through
IR, NMR and mass spectrometry. Besides this in vivo
hypolipidemic effect of the compound was also evaluated.
In vitro antioxidant property
Since, the role of free radicals in the pathogenesis of
various diseases including atherosclerosis has been well
established; the scavenging property of natural agents
or drug against free radicals is of utmost importance.
Among the eluted FVBM fractions, fraction F18 exhib-
ited significantly higher DPPH radical scavenging activity
of 51% at 5 μg/ml (Figure 1), which was much better
than standard ascorbic acid value of 12.77% at 5 μg/ml.
Moreover, the ability of these fractions to reduce ferric
ions into ferrous form, as an indicative of total antioxi-
dant capacity, were also accessed by FRAP assay. Frac-
tion F18 had significantly higher total antioxidant
capacity (3.536 μM Fe2+/gm) followed by fraction F20
(3.168 μM Fe2+/gm), while other fractions had remark-
ably less activity (Figure 2).
In vitro HMG-CoA reductase inhibitory study
It is well established that cholesterol lowering drugs
mainly act by inhibiting the enzymatic activity of HMG-
CoA reductase. Therefore, in the present study all the
eluted fractions were screened for HMG-CoA reductase
inhibitory activity following a previously standardizedFigure 1 DPPH free radical scavenging activity of different FVBM frac
Mean ± SD (n=3). Non-significant (ns), significantly different at *P < 0.05, **Pprotocol [20,43]. Among all the eluted fractions, fraction
F6, F15, F18, and F20 showed marked HMG-CoA reduc-
tase inhibition activity with 73.3%, 85.2%, 98.5% and
98.1% inhibition, respectively, at 5 μg/ml (Figure 3). The
fraction F18 due to better antioxidant activity and anti-
HMG-CoA reductase property was selected for further
study. This fraction has IC50 value of 84 ± 2.8 ng/ml, while
pravastatin exhibits an IC50 value of 70 nM (Figure 4). Fur-
thermore, the mode of inhibition of fraction F18 was also
analyzed by double-reciprocal Lineweaver-Burk plot ac-
cording to Michaelis-Menten kinetics. This fraction dem-
onstrated an uncompetitive mode of inhibition against
HMG-CoA reductase (Figure 5a). Ki value, determined by
Dixon plot, of fraction F18 was 84 ng/ml (Figure 5b) and
concorded with IC50 value, i.e., 84 ± 2.8 ng/ml.
Identification of the newly isolated bioactive compound
The bioactive fraction F18 was further subjected to IR, 1H
NMR, 13C NMR and mass analysis for its identification
and structure determination. The bioactive compound
was identified as n-Octadecanyl-O-α-D-glucopyranosyl
(6′→ 1″)-O-α-D-glucopyranoside. The 1H NMR data
showed that this fraction was approximately 95% pure. It
gave positive Fehling’s test for glucoside and showed IR
absorption bands for hydroxyl groups (3411, 3345, 3211,
3019 cm−1), ester function (1626 cm−1) and aliphatic chain
(756 cm−1). On the basis of mass and 13C NMR spectra,
the molecular ion peak was identified at m/z 594 [M]+ in
consistence with the molecular formula of acyl digluco-
side, C30H58O11 (Figure 6). The
1H NMR spectrum of
F-18-FVBM displayed two one-proton doublets at δ 5.38
(J=4.2 Hz) and 5.11 (J=7.0 Hz) assigned to anomeric H-1′
and H-1′ protons and two two-proton doublets at δ 3.34
(J=6.9, 9.3 Hz) and 3.09 (J=7.5, 6.6 Hz) respectively, other
sugar proton from δ 3.96 to 3.30, two two-proton triplet
at δ 3.43 (J=6.3 Hz) and 1.99 (J=10.8 Hz) attributed to
methylene H2-6′ proton adjacent to the ester group, other
methylene proton as one proton multiplet from δ 4.63 totions (F1-F20) and ascorbic acid (AA). Values are represented as
< 0.01, ***P < 0.001 vs 0 μg/ml.
Figure 2 Ferric reducing antioxidant power of different FVBM fractions. Values are represented as Mean ± SD (n=3).
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let at δ 1.62 and a three proton triplets at δ 0.87
(J=6.2 Hz) accounted to C-18 primary methyl protons.
The 13C NMR spectrum of fraction F18 exhibited signals
for ester carbons at δ 171.52 (C-1), anomeric carbons at
δ 103.27 (C-1′) and 93.32 (C-1″), other sugar carbons
between δ 83.39-62.90, methylene carbons from δ 33.88 to
22.55 and methyl carbon at δ 14.61 (C-16). The presence of
C-2′ carbon signal in the deshielded region at δ 83.39 indi-
cated attachment of the second sugar unit at C-2′. The ab-
sence of any signal beyond δ 4.04 in the 1H NMR spectrum
and from δ171.52 to 103.27 in the 13C NMR spectrum sug-
gested saturated nature of the compound (Additional file 1:
Figure S1, Additional file 2: Figure S2, Additional file 3:
Figure S3 and Additional file 4: Figure S4). On the basis
of this evidence the active compound in fraction F18
was determined as n-Octadecanyl-O-α-D-glucopyranosyl
(6′→ 1″)-O-α-D-glucopyranoside (Figure 6).Figure 3 In-vitro HMG-CoA reductase inhibitory activity of FVBM fract
significantly different at *P < 0.05, **P < 0.01, ***P < 0.001 vs 0 μg/ml.In-silico study of bioactive compound with HMG-CoA reductase
To further corroborate our findings, the molecular inter-
action studies were carried out to find out the plausible
ligand-receptor interactions between the inhibitor
and HMG-CoA reductase. The docked structures of
pravastatin-HMG-CoA reductase were found to be sur-
rounded by Ser684, Asp690, Arg590, Lys735 and Glu559
amino acid residues, which play important role in stabil-
izing the complex, whereas n-Octadecanyl-O-α-D-
glucopyranosyl(6′→ 1″)-O-α-D-glucopyranoside-HMG-CoA
reductase complex involved contributions from residues
Asn755, Asp765, Lys691, Glu559, Gly560, Ala525, Arg590, which
are not from the catalytic domain of HMG-CoA reductase.
This observation indicated an uncompetitive mode of
inhibition. The non-catalytic site accommodated the
compound (Table 3) with a dominant nonelectrostatic
energy contribution. The inhibitor showed binding energy
of–5.58 Kcal/mol indicating high affinity for the bindingions. Values are represented as Mean ± SD (n=3). Non-significant (ns),
Figure 4 Spectrophotometric time-scans demonstrating the ability of fraction F18 (n-Octadecanyl-O-α-D-glucopyranosyl (6′→ 1″)-O-α-
D-glucopyranoside) (a) and pravastatin (b) to inhibit HMG-CoA reductase activity.
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(ΔG:–6.25 kcal/mol) (Figure 7 and Table 3).
ADME predictions
ADME predictions study of novel compound was done to
analyze its pharmacokinetic properties such as aqueous
solubility, intestinal absorption, plasma protein binding,
blood–brain-barrier penetration, hydrogen bond donor,
hydrogen bond acceptor and cytochrome P450 inhibition
(Table 4). A comparison between these results and the
standard values revealed that this bioactive compound has
a good aqueous solubility, undefined blood–brain-barrier
penetration, low intestinal absorption, <90% plasma pro-
tein binding, no inhibition effect on cytochrome P450 and
extremely low hepatotoxicity.
LDH release assay
There was no significant increase in LDH released fol-
lowing incubation of blood platelets with either the test
drug F18 or the atorvastatin. 4.3% of LDH was released
in the incubation medium containing hemoglobin and
F18. F18 induced weak LDH leakage suggesting that atconcentration of 1 mg F18 was not cytotoxic. Moreover,
when compared with the standard, at a concentration of
1 mg there is a released of only 3.7% of LDH in the in-
cubation medium. Around 4% LDH leakage is supposed
to be weak in cytotoxicity and hence can be said as non-
cytotoxic at this concentration (Table 5).
In vivo hypolipidemic study
The efficacy of FVBM extract (50 and 100 mg/rat), iso-
lated bioactive compound (1 mg/rat) and standard
(Atorvastatin, 1 mg/rat) in ameliorating the lipid level
was elucidated in Triton WR-1339 induced hyperlipid-
emic rats after 18 h of treatment. A significant increase
in TG (298%), TC (377%) and non HDL-C (592%) levels
in Triton WR-1339 induced hyperlipidemic rats was ob-
served in comparison to NC rats (Table 6). After treat-
ment TG, TC & non-HDL-C levels were markedly
decreased by 74%, 77% and 83% respectively in the bio-
active compound treated group, which was almost com-
parable to the reduction observed in AT group at the
same dose of 1 mg/rat. Furthermore, plasma LDL-C and
VLDL-C levels were significantly increased from the
Figure 5 Lineweaver-Burk double reciprocal plot (a) and Dixon plot (b) of fraction F18 (n-Octadecanyl-O-α-D-glucopyranosyl (6′→ 1″)-
O-α-D-glucopyranoside) against HMG-CoA reductase.
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48 mg/dl respectively in Triton WR-1339 induced hyper-
lipidemic rats (Table 7). Whereas, the HDL-C value was
significantly reduced by 20% in HLC group, when com-
pared to rats in the control group. After the treatment, a
significant decrease of 71%, and 60% in LDL-C, and 86%
and 71% in VLDL-C was observed in FVT-1 and FVT-2
groups respectively, when compared to HLC group.
Moreover, hyperlipidemic rats treated with bioactive
compound (CT) showed marked reduction in LDL-C
(85%) and VLDL-C (74%) levels, when compared to
HLC group, which is almost comparable to the reduc-
tion observed in groups treated with high dose of plant
extract (FVT-2: 100 mg/rat) and atorvastatin (1 mg/rat).
In contrast the HDL-C level was significantly increasedby 19%, 35%, 28% and 29% in FVT-1, FVT-2, CT and
AT groups, when compared to HLC control rats. These
results demonstrated that the plant extract at higher
dose (FVT-2), the bioactive compound and atorvastatin
were almost equally effective in ameliorating plasma
lipid levels.
HDL-C/TC, HDL-C/LDL-C, TC/HDL-C and LDL-C/
HDL-C ratios calculated from the data presented in
Tables 6 and 7 are shown in Table 8. A significant de-
crease of 5.89 and 9.74 fold in HDL-C/TC and HDL-C/
LDL-C ratios was observed; whereas, a marked increase
in TC/HDL-C and LDL-C/HDL-C ratios was observed
in HLC group in contrast to the normal ratios. After the
treatment, the decrease in HDL-C/TC and HDL-C/LDL-
C ratio was significantly prevented and increased to
Figure 6 The structure of bioactive fraction F18 (n-Octadecanyl-O-α-D-glucopyranosyl(6′→ 1″)-O-α-D-glucopyranoside).
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FVT-2 group. Furthermore, atorvastatin and bioactive
compound treated rats also exhibited marked increase of
5.42, 8.19 and 5.90, 9.43 fold in HDL-C/TC and HDL-C/
LDL-C ratio. An opposite pattern was observed in TC/
HDL-C and LDL-C/HDL-C ratios. These ratios were sig-
nificantly increased by 5.88 and 9.73 fold in HLC group,
when compared to the normal value of 2.75 mg/dl and
1.29 mg/dl, respectively. All the treated groups showed a
significant reduction in TC/HDL-C and LDL-C/HDL-C
ratios when compared to the ratios of HLC group. These
results indicated a significant restoration of these ratios
close to the normal values, which in turn indicated the
normalization of cholesterol level associated with the
studied lipoproteins.
The hepatic HMG-CoA reductase activity in Triton
WR-1339 induced hyperlipidemic HLC rats was signifi-
cantly increased by 3.59 fold when compared to NC rats
(Table 9). Administration of plant extract in two differ-
ent doses resulted in a significant decrease in HMG-
CoA reductase activity by 2.06 and 3.50 fold respectively,
when compared to HLC value. It is noteworthy that iso-
lated compound exerted better and significant reduction
(3.18 fold) than the atorvastatin (2.18 fold), when com-
pared to HLC control group. These results demonstrated
that the decrease in cholesterol level of Triton WR-1339
induced hyperlipidemic rats was due to the decline in
enzymatic activity of HMG-CoA reductase activity.Table 3 Molecular interaction studies of F18 bioactive
compound and standards with HMG-CoA reductase











2 Pravastatin −6.25 SER684, LYS735,
ARG590, ASP690,
GLU560, ASN658Discussion
It is well accepted that enzymes are the major regulators
of the lipid metabolism; wherein HMG-CoA reductase is
one of the most clinically important enzymes involved in
the cholesterol biosynthetic pathway. Changes in the re-
ductase activity are closely related to changes in the
overall rate of cholesterol synthesis. This suggests that
the inhibition of HMG-CoA reductase would be an ef-
fective mean to lower plasma cholesterol [44]. Thus, this
enzyme is the target of the widely available cholesterol-
lowering drugs known, collectively, as statins [45]. Al-
though, most of the HMG-CoA reductase inhibitors
have some adverse side effects [12,13].
In the same vein, oxidative stress also plays a pivotal
role in atherosclerosis and subsequent CVD. Therefore,
finding an HMG-CoA reductase inhibitor with antioxi-
dant property is of great potential in the treatment and
management of hypercholesterolemia and cholesterol in-
duced oxidative stress. The medicinal plants are now be-
ing seen as a potent source of the drug discovery
program. Epidemiologic studies have shown a correl-
ation between an increased consumption of phenolic an-
tioxidants and a reduced risk of CVD [46-49]. The
current interest in combating free radical mediated dis-
eases including atherosclerosis has been shifted toward
natural products. The present work was an extension of
our recent study in which we screened stem bark and
leaf extracts of Ficus virens for an HMG-CoA reductase
inhibitory activity. Among all the sequentially extracted
fractions, FVBM extract showed most potent antioxi-
dant, genoprotective, and HMG-CoA reductase inhibi-
tory activity (IC50 value: 3.45 ± 0.45 μg/ml) [20]. In the
present study, FVBM extract was subjected to a column
chromatography in order to identify and isolate the
bioactive compounds as well as to examine their antioxi-
dant and HMG-CoA reductase inhibitor property. More-
over, the role of most potent isolated fraction and the
FVBM extract was also investigated in Triton WR-1339
induced hyperlipidemic rats. Twenty fractions (F1-F20)
of FVBM extract were collected through column chro-
matography and screened for antioxidant and HMG-
Figure 7 Binding pattern studies of standard (a) and n-Octadecanyl-O-α-D-glucopyranosyl (6′→ 1″)-O-α-D-glucopyranoside (b) with
HMG-CoA reductase.

















F18 3 3 4 0 0 0 3.863 11 7
Atorvastatin 2 2 4 1 1 1 4.701 7 4
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Table 5 Effect of F18, and atorvastatin on total lactate
dehydrogenase released in the incubation medium
Incubation time (Min.) Control Atorvastatin (1 mg) F18 (1 mg)
0 0 ± 0.00 0 ± 0.000 0 ± 0.000
30 0.4 ± 0.30 1.1 ± 0.25 1.3 ± 0.23
60 1.1 ± 0.25 2.0 ± 0.24 2.2 ± 0.35
90 1.6 ± 0.22 3.1 ± 0.31 3.7 ± 0.41
120 2.6 ± 0.24 3.7 ± 0.36 4.3 ± 0.37
Results are presented as mean ± SD.
Table 7 Effect of FVBM, F18 bioactive compound and
atorvastatin on plasma LDL-C, HDL-C and VLDL-C in
Triton WR-1339 induced hyperlipidemic rats after
18 hours of treatment
Group LDL-C HDL-C VLDL-C
NC 35.5 ± 1.12* 27.5 ± 0.99 12 ± 0.67
HLC 280.12 ± 4.36* 22.28 ± 0.56 48.26 ± 1.45
(+646.66%)a (−20%)a (+300.04%)a
FVT-1 81.15 ± 2.19* 26.63 ± 0.74 19.09 ± 0.81
(−71.07%)a (+19.3%)a (−60.41%)a
FVT-2 39.5 ± 1.37* 29.7 ± 1.15 13.08 ± 0.64
(−85.89%)a (+35%)a (−71.40%)a
CT 43.26 ± 1.25* 28.2 ± 1.14 12.54 ± 0.63
(−84.55%)a (+28.18%)a (−74.01%)a
AT 37.88 ± 1.18* 28.4 ± 1.15 11.72 ± 0.52
(−86.47%)a (+29.09%)a (−75.71%)a
*Values are mean (mg/dl) ± SD from LDL-C, HDL-C and VLDL-C, isolated from
plasma of 5 rats in each group.
NC, normal control; HLC, triton induced hyperlipidemic control; FVT-1, fed
50 mg FVBM extract/rat; FVT-2, fed 100 mg FVBM extract/rat; CT, fed 1 mg F18
bioactive compound/rat and AT, given 1 mg atorvastatin/rat once.
Significantly different from NC at ap < 0.001.
Significantly different from HLC at ap < 0.001.
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methods are frequently used for screening the antioxi-
dant potency of plants [21-23]. DPPH is a stable free
radical commonly used to evaluate free radical scaven-
ging activity of antioxidants. The fraction F18 exhibited
higher radical scavenging activity of 51% at 5 μg/ml than
the other fractions and standard ascorbic acid (12.7% at
5 μg/ml). The ability of this fraction to reduce ferric ions
to ferrous ions, generally used to determine the antioxi-
dant power, was also evaluated and it showed significantly
higher antioxidant capacity in comparison to other frac-
tions similar to earlier reports [18-20]. As discussed,
HMG-CoA reductase is a major regulatory enzyme of
cholesterol biosynthetic pathway; and majority of lipid
lowering drugs work by inhibiting the activity of this en-
zyme. Employing a previously standardized protocol
[20,43], a marked HMG-CoA reductase inhibitory activity
with an IC50 value of 84 ± 2.8 ng/ml was observed in frac-
tion F18. Here it is interesting to mention that F18Table 6 Effect of FVBM extract, F18 bioactive compound
and atorvastatin on plasma triglycerides, total cholesterol
and non-HDL-cholesterol in Triton WR-1339 induced
hyperlipidemic rats after 18 hours of treatment
Group Triglycerides Total cholesterol Non-HDL-cholesterol†
NC 60.45 ± 1.22* 75.86 ± 1.32 47.5 ± 1.17
HLC 240.74 ± 3.36* 361.92 ± 4.86 328.38 ± 3.6
(+298.24%)a (+377.08%)a (+591.32%)a
FVT-1 95.47 ± 2.69* 126.17 ± 2.8 100.24 ± 2.5
(−60.34%)a (−65.13%)a (−69.47%)a
FVT-2 65.42 ± 1.17* 84.25 ± 1.25 53.3 ± 1.19
(−72.82%)a (−76.79%)a (−83.76%)a
CT 62.7 ± 1.48* 84.5 ± 2.25 55.8 ± 1.12
(−73.95%)a (−76.65%)a (−83.00%)a
AT 58.6 ± 1.15* 78.23 ± 1.25 49.6 ± 1.18
(−75.65%)a (−78.38%)a (−81.85%)a
†For the calculation of non-HDL-C, data is taken from Tables 5 and 6.
*Values are mean (mg/dl) ± SD from plasma of 5 rats in each group.
NC, normal control; HLC, triton induced hyperlipidemic control; FVT-1, fed
50 mg FVBM extract/ rat; FVT-2, fed 100 mg FVBM extract/ rat; CT, fed 1 mg F18
bioactive compound/ rat and AT, given 1 mg atorvastatin/rat once.
Significantly different from NC at ap < 0.001.
Significantly different from HLC at ap < 0.001.fraction exhibited better IC50 value than that of FVBM
crude extract [20]. To the best of our knowledge and on
the basis of literature review, the demonstrated HMG-
CoA reductase inhibitory activity was significantly better
than the reported inhibitors from various plants like kiwi-
fruit [50], Quercus infectoria, Rosa damascene and Myrtus
communis [51], indicating its potent hypolipidemic prop-
erty. The fraction F18 was identified as Octadecanyl-O-α-
D-glucopyranosyl (6′→ 1″)-O-α-D-glucopyranoside. This
is a new and completely different structure than the other
inhibitors isolated from various plants such as tocotrienol
from barley [52], kakkalide and irisolidone from flower of
Pueraria thunbergiana [53], camphene, a plant-Derived
monoterpene [54], daidzein from Pueraria thunbergiana
[55], acetylenic acids from the root bark of Paramacrolo-
bium caeruleum [56], and flavonoids from the buds of
Rosa damascena [57].
Furthermore, to understand the binding mechanism and
corroborate our in vitro hypothesis, in silico molecular
interaction studies were conducted between HMG-CoA
reductase and the inhibitor F18. The docked structure of
F18-HMG-CoA reductase involved contributions from
Asn755, Asp765, Lys691, Glu559, Gly560, Ala525, Arg590 resi-
dues, which were not from the catalytic domain of the en-
zyme. This confirms the uncompetitive mode of inhibition
observed in vitro.
The result of interaction study of standard drug prava-
statin with HMG-CoA reductase is in consensus with
our previously published data [20,43,58]. In addition, this
novel F18 compound showed good aqueous solubility,
Table 8 Effect of FVBM, F18 bioactive compound and atorvastatin on the ratios of plasma HDL-C/TC, HDL-C/LDL-C,
TC/HDL-C and LDL-C/HDL-C in Triton WR-1339 induced hyperlipidemic rats after 18 hours of the treatment
Group/Ratio† HDL-C/TC HDL-C/LDL-C TC/HDL-C LDL-C/ HDL-C
NC 0.3625 ± .025* 0.7746 ± 0.088 2.758 ± 0.105 1.2909 ± 0.0576
HLC 0.0615 ± 0.003* 0.0795 ± 0.0074 16.244 ± 0.76 12.5727 ± 0.65
(−5.89 f)a (−9.74 f)a (+5.88 f)a (+9.73 f)a
FVT-1 0.2110 ± 0.0048* 0.3281 ± 0.0075 4.737 ± 0.094 3.0473 ± 0.086
(+4.13 f)a (−3.43 f)a (−4.12 f)a(+3.43 f)a
FVT-2 0.3525 ± 0.0071* 0.7518 ± 0.074 2.836 ± 0.115 1.3299 ± 0.034
(+9.45 f)a (−5.72 f)a (−9.45 f)a(+5.73 f)a
CT 0.3337 ± 0.0042* 0.6518 ± 0.015 2.996 ± 0.081 1.5340 ± 0.0691
(+8.19 f)a (−5.42 f)a (−8.21 f)a(+5.42 f)a
AT 0.3630 ± 0.0036* 0.7497 ± 0.028 2.754 ± 0.129 1.3338 ± 0.064
(+9.43 f)a (−5.89 f)a (−9.42 f)a(+5.90 f)a
†For the calculation of ratios, data is taken from Tables 5 and 6.
*Values are mean (mg/dl) ± SD from plasma of 5 rats in each group.
NC, normal control; HLC, triton induced hyperlipidemic control; FVT-1, fed 50 mg FVBM extract/rat; FVT-2, fed 100 mg FVBM extract/rat; CT, fed 1 mg F18 bioactive
compound/rat and AT, given 1 mg atorvastatin/rat once.
‘f’ stands for fold.
Significantly different from NC at ap < 0.001.
Significantly different from HLC at ap < 0.001.
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sorption, <90% plasma protein binding, no inhibition
effect on cytochrome P450 and extremely low hepatotox-
icity, indicating it to be safe as a potential drug. In
addition, the novel compound also showed weak LDH
release which indicates that it is non cytotoxic at con-
centration of 1 mg.Table 9 Effect of FVBM, F18 bioactive compound and
atorvastatin on in vivo modulation of hepatic HMG-CoA
reductase activity in Triton WR-1339 induced hyperlipidemic
rats after 18 hours of the treatment
Group HMG-CoA reductase activity†
NC 4.35 ± 0.22*
HLC 1.21 ± 0.041*
(+3.59 f)a
FVT-1 2.499 ± 0.057*
(−2.06 f)a
FVT-2 4.24 ± 0.15*
(−3.50 f)a
CT 3.85 ± 0.13*
(−3.18 f)a
AT 2.64 ± 0.075*
(−2.18 f)a
†Expressed as ratio of HMG-CoA to Mevelonate; lower the ratio higher the
enzyme activity.
*Values are mean ± SD from liver homogenate of 5 rats in each group.
NC, normal control; HLC, triton induced hyperlipidemic control; FVT-1, fed
50 mg FVBM extract/rat; FVT-2, fed 100 mg FVBM extract/rat; CT, fed 1 mg F18
bioactive compound/rat and AT, given 1 mg atorvastatin/rat for once.
Significantly different from NC at ap < 0.001.
Significantly different from HLC at ap < 0.001.Based on the above in vitro and in silico rationale,
in vivo study was designed to evaluate the hypolipidemic
properties of FVBM extract, bioactive compound and
standard drug atorvastatin in the triton-induced hyper-
lipidemic rat model. The triton-induced hyperlipidemic
rat model has been successfully employed to evaluate
antidyslipidemic activity [59,60]. Triton WR-1339 is a
non-ionic surfactant, which elevates the plasma lipids on
administration, causes changes in circulatory lipopro-
teins, suppresses lipoprotein lipase (LPL) activity, hinders
the uptake of circulating lipids by extra hepatic tissues,
and increases the HMG-CoA reductase activity resulting
in increased blood lipid concentrations, hence hyperlipid-
emia. The present study demonstrated a significant increase
in TG, TC, VLDL-C and LDL-C levels with a decrease in
HDL-C value in triton-induced hyperlipidemic rats, which
was in agreement with previously published data [61]. This
increase in plasma TG and TC by triton was due to in-
crease in HMG-CoA reductase activity and by inhibition of
lipoprotein lipase responsible for hydrolysis of plasma lipids
[60,62]. FVBM extract at higher dose (100 mg/rat) and F18
compound effectively blocked the increase in TG, TC,
LDL-C and non-HDL-C levels and reversed them to nor-
mal values; thus showed a comparable effect with atorva-
statin. Moreover, the HDL-C level was also significantly
increased after treatment with the plant extract and F18
compound which in turn offered better protection to LDL
as well as HDL from oxidative stress through its associated
antioxidant enzyme paraoxonase (PON) [63,64].
It has been established that LDL-C/HDL-C and HDL-C/
TC ratios are good predictors of presence and severity of
CAD [65]. We observed a significant decrease in HDL-C/
Iqbal et al. Lipids in Health and Disease  (2015) 14:15 Page 13 of 15LDL-C and HDL-C/TC ratio and increase in TC/HDL-C
and LDL-C/HDL-C ratios in hyperlipidemic control rats.
The ratios related to TC, LDL-C and HDL-C in FVT-2 &
F18 treated groups were positively modulated and restored
similar to corresponding ratio values in NC. These results
indicate that therapeutic amelioration in plasma TC by F18
or FVBM could be attributed to the changes mainly in LDL-
C levels, which emphasize the usefulness of these agents in
decreasing cardiovascular morbidity and mortality [66].
The significant increase in plasma and lipoprotein lipid
levels in triton induced hyperlipidemic rats is consistent
with the increase in hepatic HMG-CoA reductase activity.
Earlier studies have demonstrated that intravenous or
intraperitoneal injection of Triton WR-1339 increases
hepatic cholesterol synthesis by increasing HMG-CoA re-
ductase activity, the rate limiting enzyme in the choles-
terol biosynthetic pathway in rodents [67,68]. Treatment
of hyperlipidemic rats with FVBM extract (at higher dose)
and fraction F18 significantly alleviated the increased lipid
levels and restored them close to the normal values, it
may provide a mechanism of reduction of plasma choles-
terol level in triton induced hyperlipidemic rat model. Our
results are in concordance with earlier reports demon-
strating that the reduction in HMG-CoA reductase activ-
ity is responsible for the hypolipidemic property of natural
agents [53,58,69]. This lipid lowering activity might be due
to the pleiotropic effect that the compound exhibits
through reduced HMG-CoA reductase activity, with sig-
nificant antioxidant property and increased lipoprotein
lipase activity. The compound F18 showed, at an equiva-
lent dose of drug atorvastatin, marked hypolipidemic
property and might be a drug candidate.
Conclusion
In conclusion, our in vitro, in silico and in vivo results
clearly demonstrated the therapeutic efficacy of novel
HMG-CoA reductase inhibitor (F18-n-Octadecanyl-O-α-
D-glucopyranosyl(6′→ 1″)-O-α-D-glucopyranoside) over
statins as a substitute against hyperlipidemia. Moreover,
being a natural agent with potent antioxidant and hypolip-
idemic property, this compound could be used in the pro-
tection of ROS/free radical-induced oxidative damage,
hyperlipidemia/dyslipidemia and atherosclerotic complica-
tions. However, further large scale preclinical and clinical
trials are needed to set up its lipid lowering and anti-
atherosclerotic properties.Additional files
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